The Centers for Medicare & Medicaid Services (CMS) has made America's Medicare drug price negotiation programme permanent. In a final rule issued on Thursday, November 5, 2026 — rule CMS-4215-F — the federal agency wrote the programme's procedures into federal regulation for negotiated prices taking effect in 2029 and later years, replacing the temporary guidance under which the first rounds were run.
Source: CMS press release, Nov. 5, 2026
"President Trump directed us to lower drug costs for Americans using every tool at our disposal," CMS Administrator Dr. Mehmet Oz said in the agency's announcement. "This rule provides additional tools to help CMS negotiate better deals, achieve greater savings for taxpayers and beneficiaries, and improve health outcomes for seniors who rely on the Medicare Prescription Drug Program."
The deadline that matters most: 20 more drugs by February 1, 2027
Under the rule, CMS will select up to 20 additional negotiation-eligible drugs covered under Medicare Part D and/or payable under Part B by February 1, 2027, for the programme's fourth negotiation cycle. The agency may also pick drugs negotiated in earlier cycles for renegotiation. Negotiations will run through 2027, the agreed maximum fair prices must be published by November 30, 2027, and those prices take effect on January 1, 2029.
Source: CMS final rule fact sheet
Why a permanent rule was needed
The Negotiation Program was created by sections 11001 and 11002 of the Inflation Reduction Act of 2022, which for the first time authorised Medicare to negotiate what the law calls maximum fair prices (MFPs) for certain high-expenditure, single-source drugs. For the first three cycles — covering price years 2026, 2027 and 2028 — Congress directed CMS to run the programme through guidance documents rather than formal regulation. That authority expires after 2028, so without this rule there would have been no settled legal framework for the 2029 round and beyond.
The timing is immediate for patients as well as lawyers: the second round of negotiated prices — for 15 more Part D drugs, including Ozempic, Wegovy, Trelegy and Xtandi — takes effect on January 1, 2027, two months from now. CMS has projected about $685 million in out-of-pocket savings for enrollees in 2027 from that round alone, a figure cited in health-policy summaries of the agency's announcements.
The anti-circumvention clause drugmakers are watching
The rule finalises a policy CMS first proposed in June on fixed combination drugs. Where CMS determines that a fixed combination product is a new formulation of an existing drug — for example, the same maker's product with an added ingredient such as hyaluronidase that enables a new route of administration, such as subcutaneous instead of intravenous use — the products are treated together for selection purposes. CMS says the policy closes an incentive for a manufacturer to shift patients onto a new formulation to escape the maximum fair price. Pharmaceutical Commerce's analysis notes the rule also clarifies how the seven- and 11-year periods since approval are measured for drugs formerly covered by the orphan-drug exclusion. Bloomberg Law reported the provision opens the door to fresh legal challenges from pharmaceutical companies; that is a prediction in trade reporting, not a filed case, and no lawsuit over this rule had been reported as of Friday.
Source: Pharmaceutical Commerce, Nov. 6, 2026
Small biotech floor, pharmacy shelves and pharmacy bills
Three further provisions matter at the counter. First, the rule implements the Temporary Floor for Small Biotech Drugs required by law: for price years 2029 and 2030, CMS may not offer or accept a counteroffer below a specified floor for certain eligible small-biotech drugs. Second, Part D plans must include selected drugs with a maximum fair price in effect on their formularies — a negotiated drug cannot simply be left off the shelf. Third, the prices Part D plans pay pharmacies and other dispensing entities for those drugs are capped at the maximum fair price plus any dispensing fees.
Source: Becker's Hospital Review, Nov. 5, 2026
The American Hospital Association told CMS in August 17 comments on the proposed rule that drugmakers should be required to provide the maximum fair price at the point of sale rather than through retrospective rebates, warning a rebate approach would burden hospitals — especially rural, critical-access and safety-net facilities — and could spill into the 340B programme. The final rule's pharmacy-payment cap addresses what plans pay dispensing entities; hospitals' wider point-of-sale demand remains a live lobbying issue.
What this means for Punjabi and diaspora families
Prescription costs are a household issue in Punjabi-American families, where many seniors are on Medicare Part D and adult children routinely help parents compare plans, formularies and pharmacy bills across California's Central Valley, New York, New Jersey, Texas and other diaspora centres. This rule does not change any price a patient pays today — current negotiated prices follow the earlier cycles — but it locks in the machinery that will decide prices from 2029 onward, guarantees that negotiated drugs stay on Part D formularies, and caps what plans can charge through pharmacies above the negotiated price plus dispensing fees. Families should watch the February 1, 2027 selection list: if a parent's high-cost drug is among the up to 20 chosen, its negotiated price would apply from January 1, 2029.
What happens next
The final rule is scheduled for publication in the Federal Register on November 9, 2026 (document 2026-22792) and takes effect on December 5, 2026. Guidance continues to govern the 2026–2028 cycles. CMS's next hard deadline is the February 1, 2027 selection of up to 20 drugs for the fourth cycle, followed by negotiations during 2027 and publication of agreed prices by November 30, 2027. Industry legal challenges, if filed, would be the next development to watch.